A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα-positive solid tumours: Results in the endometrial cancer (EC) cohort

被引：2

作者：

Cristea, M. C. ^{[1
]}

Frankel, P. ^{[2
]}

Synold, T. ^{[3
]}

Stewart, D. B. ^{[1
]}

Wang, E. ^{[1
]}

Jung, A. ^{[4
]}

Wilczynski, S. ^{[5
]}

Tran, M. ^{[5
]}

Konecny, G. E. ^{[6
]}

Eng, M. ^{[7
]}

Kilpatrick, L. ^{[8
]}

Chen, Y-J. ^{[9
]}

Glaser, S. ^{[9
]}

Han, E. ^{[10
]}

Dellinger, T. ^{[10
]}

Hakim, A. ^{[10
]}

Lee, S. ^{[10
]}

Morgan, R. J. ^{[1
]}

Rodriguez, L. ^{[10
]}

Wakabayashi, M. ^{[10
]}

机构：

[1] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA

[2] City Hope Comprehens Canc Ctr, Dept Computat & Quantitat Med, Duarte, CA USA

[3] City Hope Natl Med Ctr, Canc Biol, Duarte, CA USA

[4] City Hope Comprehens Canc Ctr, Diagnost Radiol, Duarte, CA USA

[5] City Hope Comprehens Canc Ctr, Div Program, Duarte, CA USA

[6] Univ Calif Los Angeles, Dept Med, David Geffen Sch, Los Angeles, CA 90024 USA

[7] City Hope Natl Med Ctr, Div Program, Duarte, CA USA

[8] City Hope Natl Med Ctr, Shared Rsc Clin Trial Off, Duarte, CA USA

[9] City Hope Comprehens Canc Ctr, Radiat Oncol, Duarte, CA USA

[10] City Hope Comprehens Canc Ctr, Surg, Duarte, CA USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

863P

引用

页码：S639 / S639

页数：1

共 50 条

[1] A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected frα-positive solid tumors: Results in the ovarian cancer (EC) cohort.
Cristea, Mihaela C.
Ruel, Nora H.
Frankel, Paul Henry
Synold, Timothy W.
Stewart, Daphne B.
Wang, Edward Wenge
Jung, Alex
Wilczynski, Sharon
Tran, Michael
Konecny, Gottfried E.
Eng, Melissa
Kilpatrick, Lindsay
Chen, Yi-Jen
Glaser, Scott
Dellinger, Thanh Hue
Hakim, Amy
Lee, Stephen
Morgan, Robert
Han, Ernest Soyoung
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] PHASE I STUDY OF MIRVETUXIMAB SORAVTANSINE (MIRV) AND RUCAPARIB FOR RECURRENT ENDOMETRIAL, OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
Backes, F.
Fowler, J.
Copeland, L.
Wei, L.
O'Malley, D.
Cohn, D.
Cosgrove, C.
Hays, J.
Bixel, K.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A13 - A14
[3] A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
Cristea, Mihaela C.
Stewart, Daphne
Synold, Timothy
Ruel, Nora
Mortimer, Joanne
Wang, Edward
Jung, Alexander
Wilczynski, Sharon
Konecny, Gottfried E.
Eng, Melissa
Kilpatrick, Lindsay
Han, Ernest
Dellinger, Thanh
Hakim, Amy
Lee, Stephen
Morgan, Robert J.
Wakabayashi, Mark T.
Frankel, Paul H.
GYNECOLOGIC ONCOLOGY, 2024, 182 : 124 - 131
[4] Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer
Backes, Floor
Wei, Lai
Copeland, Larry
Cohn, David
Fowler, Jeffrey
Bixel, Kristin
Cosgrove, Casey
Hays, John
Myers, Molly
Dodd, Kelly
O'Malley, David
GYNECOLOGIC ONCOLOGY, 2021, 162 : S68 - S69
[5] A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).
Cristea, Mihaela C.
Frankel, Paul Henry
Synold, Timothy W.
Mortimer, Joanne E.
Stewart, Daphne B.
Wang, Edward Wenge
Jung, Alex
Wilczynski, Sharon P.
Konecny, Gottfried E.
Parungao, Dia
Eng, Melissa
Kilpatrick, Lindsay
Chen, Yi-Jen
Glaser, Scott
Han, Ernest Soyoung
Dellinger, Thanh Hue
Hakim, Amy
Lee, Stephen
Morgan, Robert
Wakabayashi, Mark Tsuneo
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer
O'Malley, D. M.
Richardson, D. L.
Vergote, I. B.
Gilbert, L.
Castro, C.
Provencher, D.
Matulonis, U. A.
Mantia-Smaldone, G.
Martin, L.
Zweidler-Mckay, P. A.
Moore, K. N.
ANNALS OF ONCOLOGY, 2020, 31 : S626 - S627
[7] Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
Moore, K. N.
Oza, A. M.
Colombo, N.
Oaknin, A.
Scambia, G.
Lorusso, D.
Banerjee, S.
Murphy, C.
Konner, J.
Lim, P.
Prasad-Hayes, M.
Monk, B. J.
Wang, J.
Birrer, M. J.
Vergote, I. B.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S790 - S791
[8] A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).
Porter, Rebecca L.
Veneris, Jennifer Taylor
Tayob, Nabihah
West, Gabriela
Polak, Madeline
Gardner, Jeanette
Campos, Susana M.
Krasner, Carolyn N.
Lee, Elizabeth Katherine
Liu, Joyce F.
Stover, Elizabeth
Wright, Alexi A.
Matulonis, Ursula A.
Konstantinopoulos, Panagiotis A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] PHASE I EXPANSION STUDY OF MIRVETUXIMAB SORAVTANSINE, A FOLATE RECEPTOR ALPHA (FRa)-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH ENDOMETRIAL CANCER
Martin, L.
Konner, J.
O'Malley, D.
Bauer, T.
Matulonis, U.
Seward, S.
Oza, A.
Kirby, M.
Birrer, M.
Moore, K.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1975 - 1975
[10] A PHASE 2, TWO-STAGE, STUDY OF MIRVETUXIMAB SORAVTANSINE (IMGN853) IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH MICROSATELLITE STABLE (MSS) RECURRENT OR PERSISTENT ENDOMETRIAL CANCER (EC)
Porter, Rebecca
Tayob, Nabihah
Polak, Madeline
Sawyer, Hannah
Gardner, Jeanette
Campos, Susana
Krasner, Carolyn
Lee, Elizabeth
Liu, Joyce
Stover, Elizabeth
Veneris, Jennifer
Wright, Alexi
Matulonis, Ursula
Konstantinopoulos, Panagiotis
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A229 - A230

← 1 2 3 4 5 →